Equity Profile

SRRK

Scholar Rock Holding Corporation

Health CareBiotechnology$5.9B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Scholar Rock Holding Corporation is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, it aims to address unmet medical needs through its proprietary drug development platform, which is particularly relevant as the demand for advanced treatments continues to grow.

Key Metrics to Watch

Revenue Growth

Investors will be keen to see if the company is making progress in generating revenue from its drug candidates.

N/A

EPS (Earnings Per Share)

EPS is a key indicator of profitability, and any improvement or deterioration will significantly impact investor sentiment.

$-0.82

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SRRK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-11.44%

Avg Stock Reaction

+0.88%

Last Quarter Recap

In Q1 2026, Scholar Rock reported an EPS of $-0.83, slightly missing estimates. The stock reacted negatively, dropping 1.40% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to addressing investor concerns regarding revenue generation.
Plans to provide more detailed updates on drug development progress.

Expectations

Wall Street Expectations

Analysts expect a cautious outlook as Scholar Rock continues to navigate its clinical development phase. Investors are particularly focused on any signs of revenue generation.

Bull Case

If the company shows significant progress in clinical trials and improved EPS, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company fails to meet expectations on EPS or provides disappointing updates on clinical trials, the stock may face significant downward pressure.

Key Metrics to Watch

Revenue Growth

N/A

Investors will be keen to see if the company is making progress in generating revenue from its drug candidates.

EPS (Earnings Per Share)

$-0.82

EPS is a key indicator of profitability, and any improvement or deterioration will significantly impact investor sentiment.

Clinical Trial Progress

N/A

Updates on ongoing clinical trials can signal the potential success of their drug candidates and future revenue streams.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected timeline for updates on ongoing clinical trials?

The market will closely watch for any delays or advancements, as these will impact future revenue potential and investor confidence.

How does the company plan to address the recent EPS misses?

Investors will want to understand management's strategy to improve financial performance and restore market confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Scholar Rock's clinical trials to yield positive results, which could lead to a turnaround in investor sentiment.

Supporting Evidence

The options market is pricing in a 13.4% move, indicating expectations of volatility that may not align with historical performance.

Insider selling activity could suggest a lack of confidence in near-term performance, which the market may not fully appreciate.

Key Risk

If clinical trial results show significant progress, it could shift the narrative and lead to a positive reevaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to improve its financial metrics while advancing its clinical programs.

Bull Confirmed If

A reduction in EPS loss to $-0.70 or better, coupled with positive updates on clinical trials.

Bear Confirmed If

An EPS loss greater than $-0.90, indicating continued struggles in financial performance.

Pre-Earnings Positioning

Options Market

Implied Move

±13.4%

Historical Avg

±5.7%

Pricing rich

The options market is pricing in a relatively large move, suggesting that traders expect significant volatility around the earnings report.

Options are pricing ±13.4% while SRRK has averaged ±5.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.3%

Calls (38K)P/C Ratio: 0.08Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.9%, with a raw directional average of -1.5% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$3.1M

63,491 sh

4 insiders

Net

$3.1M

Net selling

Most Active Insiders· 4 open-market trades

Chief Executive OfficerHallal David
$1.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Scholar Rock beats EPS estimates and provides positive clinical trial updates, history suggests a potential stock increase of around 1.15% on the following day.

In-Line / Cautious

If the results are in line with expectations but management's commentary is cautious, the stock may see little movement or a slight decline.

Miss

If the company misses EPS estimates significantly, history suggests a potential stock decrease of around 1.15% on the following day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Management's strategy for improving EPS and revenue generation.
3Any commentary on partnerships or collaborations that could enhance drug development.
4Insights into market demand for their drug candidates.
5Plans for future funding or capital raises.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Revenue Growth

Investors will be keen to see if the company is making progress in generating revenue from its drug candidates.

N/A

EPS (Earnings Per Share)

EPS is a key indicator of profitability, and any improvement or deterioration will significantly impact investor sentiment.

$-0.82

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SRRK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-11.44%

Avg Stock Reaction

+0.88%

Last Quarter Recap

In Q1 2026, Scholar Rock reported an EPS of $-0.83, slightly missing estimates. The stock reacted negatively, dropping 1.40% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to addressing investor concerns regarding revenue generation.
Plans to provide more detailed updates on drug development progress.

Expectations

Wall Street Expectations

Analysts expect a cautious outlook as Scholar Rock continues to navigate its clinical development phase. Investors are particularly focused on any signs of revenue generation.

Bull Case

If the company shows significant progress in clinical trials and improved EPS, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company fails to meet expectations on EPS or provides disappointing updates on clinical trials, the stock may face significant downward pressure.

Key Metrics to Watch

Revenue Growth

N/A

Investors will be keen to see if the company is making progress in generating revenue from its drug candidates.

EPS (Earnings Per Share)

$-0.82

EPS is a key indicator of profitability, and any improvement or deterioration will significantly impact investor sentiment.

Clinical Trial Progress

N/A

Updates on ongoing clinical trials can signal the potential success of their drug candidates and future revenue streams.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected timeline for updates on ongoing clinical trials?

The market will closely watch for any delays or advancements, as these will impact future revenue potential and investor confidence.

How does the company plan to address the recent EPS misses?

Investors will want to understand management's strategy to improve financial performance and restore market confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Scholar Rock's clinical trials to yield positive results, which could lead to a turnaround in investor sentiment.

Supporting Evidence

The options market is pricing in a 13.4% move, indicating expectations of volatility that may not align with historical performance.

Insider selling activity could suggest a lack of confidence in near-term performance, which the market may not fully appreciate.

Key Risk

If clinical trial results show significant progress, it could shift the narrative and lead to a positive reevaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to improve its financial metrics while advancing its clinical programs.

Bull Confirmed If

A reduction in EPS loss to $-0.70 or better, coupled with positive updates on clinical trials.

Bear Confirmed If

An EPS loss greater than $-0.90, indicating continued struggles in financial performance.

Pre-Earnings Positioning

Options Market

Implied Move

±13.4%

Historical Avg

±5.7%

Pricing rich

The options market is pricing in a relatively large move, suggesting that traders expect significant volatility around the earnings report.

Options are pricing ±13.4% while SRRK has averaged ±5.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.3%

Calls (38K)P/C Ratio: 0.08Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$3.1M

63,491 sh

4 insiders

Net

$3.1M

Net selling

Most Active Insiders· 4 open-market trades

Chief Executive OfficerHallal David
$1.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Scholar Rock beats EPS estimates and provides positive clinical trial updates, history suggests a potential stock increase of around 1.15% on the following day.

In-Line / Cautious

If the results are in line with expectations but management's commentary is cautious, the stock may see little movement or a slight decline.

Miss

If the company misses EPS estimates significantly, history suggests a potential stock decrease of around 1.15% on the following day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Management's strategy for improving EPS and revenue generation.
3Any commentary on partnerships or collaborations that could enhance drug development.
4Insights into market demand for their drug candidates.
5Plans for future funding or capital raises.